Whooping cough is the childhood disease caused by the Gram negative bacterium, Bordetella pertussis. It was thought that this disease was being managed adequately by the current immunization program, but the safety of the pertussis vaccine has been recently questioned. Development of a safe replacement vaccine will require an understanding of the disease process, in particular, determining the role of the bacterial components, in the disease and as antigens. Our long term goal is to understand the molecular basis of whooping cough. Virulent B. pertussis organisms produce multiple virulence factors including several toxins. The virulence factors are all coordinately expressed under some growth conditions, and are all repressed under others. We propose to use this property to isolate mutants deficient in virulence factors using Tn5 lac, a derivative of Tn5, which fuses expression of beta galactosidase to exogenous promoters. We will screen for mutants in virulence genes by screening for kanamycin resistant Tn5 lac insertion mutants that express beta galactosidase under conditions where the virulence factors are expressed, but not when synthesis of the virulence genes is turned off. The phenotype of these mutants will be determined and the importance of the missing virulence factor will be assessed by determining the ability of the mutant to cause disease in the infant mouse model. This new methodology will increase our understanding of the disease process. This information is crucial for the development of a safe replacement vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI023695-03
Application #
3135992
Study Section
Bacteriology and Mycology Subcommittee 1 (BM)
Project Start
1986-07-01
Project End
1989-12-31
Budget Start
1989-01-01
Budget End
1989-12-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Overall Medical
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Millen, Scott H; Watanabe, Mineo; Komatsu, Eiji et al. (2015) Single Amino Acid Polymorphisms of Pertussis Toxin Subunit S2 (PtxB) Affect Protein Function. PLoS One 10:e0137379
Schneider, Olivia D; Millen, Scott H; Weiss, Alison A et al. (2012) Mechanistic insight into pertussis toxin and lectin signaling using T cells engineered to express a CD8?/CD3? chimeric receptor. Biochemistry 51:4126-37
Komatsu, Eiji; Yamaguchi, Fuminori; Abe, Akio et al. (2010) Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol 17:807-12
Millen, Scott H; Lewallen, Daniel M; Herr, Andrew B et al. (2010) Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance. Biochemistry 49:5954-67
Schneider, Olivia D; Weiss, Alison A; Miller, William E (2009) Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4. J Immunol 182:5730-9
Schneider, Olivia D; Weiss, Alison A; Miller, William E (2007) Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect Immun 75:4040-9
Rambow-Larsen, Amy A; Weiss, Alison A (2004) Temporal expression of pertussis toxin and Ptl secretion proteins by Bordetella pertussis. J Bacteriol 186:43-50
Gamage, Shantini D; Strasser, Jane E; Chalk, Claudia L et al. (2003) Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect Immun 71:3107-15
Stenson, Trevor H; Patton, Angela K; Weiss, Alison A (2003) Reduced glutathione is required for pertussis toxin secretion by Bordetella pertussis. Infect Immun 71:1316-20
Stenson, Trevor H; Weiss, Alison A (2002) DsbA and DsbC are required for secretion of pertussis toxin by Bordetella pertussis. Infect Immun 70:2297-303

Showing the most recent 10 out of 30 publications